(vianews) - the market ended the session with gensight biologics (sight.pa) rising 15.11% to €0.64 on wednesday while cac 40 fell 0.86% to €7,466.66.
about gensight biologics
gensight biologics s.a., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. the company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. its lead product candidates include lumevoq (gs010), a recombinant aav2-based gene therapy, which is in phase iii clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated nd4 gene; and gs030, which is in phase i/ii clinical trial for the treatment of retinitis pigmentosa, as well as in preclinical stage to treat dry age-related macular degeneration. the company also develops products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. gensight biologics s.a. was incorporated in 2012 and is headquartered in paris, france.
earnings per share
as for profitability, gensight biologics has a trailing twelve months eps of €-0.17.
volatility
gensight biologics's last week, last month's, and last quarter's current intraday variation average was a negative 14.64%, a negative 1.16%, and a positive 3.33%.
gensight biologics's highest amplitude of average volatility was 14.64% (last week), 4.14% (last month), and 3.33% (last quarter).
more news about gensight biologics (sight.pa).